Key points
- Revenue increased 26% to $6.0 million
- Net loss decreased 15% to $11.1 million
- Cash balance of $17.7 million at 31 December 2024
Full summary
ImpediMed Limited, a medical software technology company, has reported its financial results for the half-year ended 31 December 2024. Total revenue for the period was $6.0 million, up 26% compared to the prior corresponding period. The increase in revenue was primarily attributed to an increase in SOZO Usage Fees, which were $5.7 million in the current period compared to $4.5 million in the prior period. Gross margin as a percent of revenue was 88%, up from 87% in the prior period. Total operating expenses were $17.3 million, compared to $17.1 million in the prior period. Other income decreased from $2.4 million to $0.5 million due to a one-time government grant received in the prior period. The net loss after tax was $11.1 million, a 15% decrease from the $9.7 million loss in the prior period. Cash and cash equivalents were $17.7 million at 31 December 2024, down from $24.6 million at 30 June 2024. Net cash used in operating activities was $7.3 million, compared to $6.8 million in the prior period.